Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Immune tolerance in hemophilia can be modulated by B cell activating factor

Immune tolerance in hemophilia can be modulated by B cell activating factor

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A

CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

Freiburg immunologists decipher anti-cancer drug's mode of operation

Freiburg immunologists decipher anti-cancer drug's mode of operation

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

New analysis method could pave the way for important breakthroughs in immunotherapy

New analysis method could pave the way for important breakthroughs in immunotherapy

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Researchers analyze outcomes in patients with primary central nervous system lymphoma

High-impact clinical trial results could improve kidney-related medical care

High-impact clinical trial results could improve kidney-related medical care

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

Combination of certain drugs can do more harm than good, shows study

Combination of certain drugs can do more harm than good, shows study

Turning autoimmunity drugs into anti-cancer treatments

Turning autoimmunity drugs into anti-cancer treatments

Novel compound shows promise for ANCA-associated vasculitis

Novel compound shows promise for ANCA-associated vasculitis

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

Drug combo for untreated CLL approved by FDA based on E1912 trial

Drug combo for untreated CLL approved by FDA based on E1912 trial

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients